Back to Search
Start Over
Phase 3 Trials Show Superiority of Targeted Treatments Over Chemotherapy in Oncogene-Addicted NSCLC.
- Source :
-
Oncology Practice Management . Dec2023, Vol. 13 Issue 12, p9-11. 3p. - Publication Year :
- 2023
-
Abstract
- The article discusses three phase 3 clinical trials presented at the European Society for Medical Oncology Congress 2023, demonstrating the superiority of targeted therapies over conventional chemotherapy in patients with oncogene-addicted non–small cell lung cancer (NSCLC). The trials focused on alectinib for ALK-positive NSCLC, amivantamab for EGFR exon 20 insertion–mutated NSCLC, and selpercatinib for advanced or metastatic RET mutation–positive medullary thyroid cance.
Details
- Language :
- English
- ISSN :
- 21644403
- Volume :
- 13
- Issue :
- 12
- Database :
- Academic Search Index
- Journal :
- Oncology Practice Management
- Publication Type :
- Periodical
- Accession number :
- 174168742